Ratings by UBS (Alice Nettleton)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/12/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Buy (Buy) |
|
Details | ||
| 10/12/2026 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Neutral (N/A) |
22.38 (20.30) |
-9.29% | Details | |
| 10/12/2026 | BioAge Labs Inc | BIOA | New Coverage | Neutral (N/A) |
6.21 (4.84) |
-22.06% | Details | |
| 10/12/2026 | Shattuck Labs | STTK | New Coverage | Buy (N/A) |
5.66 (5.42) |
-4.24% | Details | |
| 10/12/2026 | Odyssey Therapeutics | ODTX | New Coverage | Buy (N/A) |
18.12 (17.17) |
-5.24% | Details | |
| 10/12/2026 | Kardigan Inc | KARD | New Coverage | Buy (N/A) |
14.20 (13.03) |
-8.24% | Details | |
| 10/12/2026 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
40.80 (35.78) |
-12.3% | Details | |
| 10/12/2026 | Ocular Therapeutix | OCUL | New Coverage | Buy (N/A) |
7.51 (6.87) |
-8.52% | Details | |
| 10/12/2026 | Evommune Inc | EVMN | New Coverage | Neutral (N/A) |
6.41 (5.17) |
-19.34% | Details | |
| 10/12/2026 | AbCellera Biologics | ABCL | New Coverage | Buy (N/A) |
12.02 (11.80) |
-1.83% | Details | |
| 10/12/2026 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
139.91 (128.75) |
-7.98% | Details | |
| 10/12/2026 | Tectonic Therapeutics Inc. | TECX | New Coverage | Neutral (N/A) |
22.75 (20.65) |
-9.23% | Details | |
| 10/12/2026 | Spyre | SYRE | New Coverage | Buy (N/A) |
79.90 (79.90) |
0% | Details |
